You are here: Industry Insights > NHS

News List

UK Health Security Agency launches to address ‘future health threats’ pharmatimes
March 26, 2021
The Department of Health and Social Care (DHSC) has announced the launch of a new national agency to address external health threats – the UK Health and Security Agency (UKHSA).
New oral chronic lymphocytic leukaemia treatment made available on NHS europeanpharmaceuticalreview
March 22, 2021
AstraZeneca’s Calquence (acalabrutinib), a chemotherapy-free monotherapy, will be offered to patients with chronic lymphocytic leukaemia.
‘Formal review’ of GP access arrangements needed, says Healthwatch pharmatimes
March 22, 2021
A new report from Healthwatch has highlighted the need for a review of GP access arrangements, after finding many people have struggled to access care from their GP practice during the COVID-19 pandemic.
UK approval for Daiichi Sankyo’s cholesterol-lowering treatments pharmatimes
March 18, 2021
Daiichi Sankyo’s cholesterol-lowering drugs Nilemdo and Nustendi have been approved by the UK National Institute for Health and Care Excellence (NICE) for use on the NHS.
Further work needed to develop NHS health technology approaches, report finds pharmatimes
March 17, 2021
A new report from the Health Foundation suggests that further work is needed to assess and develop health technology approaches before they are implemented in the NHS following the COVID-19 pandemic.
NHS Staff Survey shows ‘profound impact’ of COVID-19 pandemic on workforce pharmatimes
March 12, 2021
The annual NHS Staff Survey has raised concerns over the wellbeing of the NHS workforce, demonstrating the toll that the COVID-19 pandemic has taken on front-line staff.
NHS England breast cancer wait times are ‘deeply worrying’ pharmatimes
March 12, 2021
NHS England cancer waiting times data from January shows that all targets for breast cancer have been missed, including two week wait targets as well as 31 day and 62 day targets.
SMC accepts Zolgensma and Rozlytrek for use by NHS Scotland pharmatimes
March 10, 2021
The Scottish Medicines Consortium (SMC) has accepted Novartis Gene Therapies' Zolgensma and Genentech’s Rozlytrek for use by NHS Scotland as part of its March 2021 decisions.
NHS England agrees deal with Novartis for access to SMA gene therapy Zolgensma pharmatimes
March 08, 2021
NHS England and Novartis Gene Therapies have signed a ‘landmark’ agreement that will make Zolgensma available for patients on the NHS.
NICE rejects Kyowa Kirin’s rare blood cancer drug Poteligeo for NHS use pharmaceutical-technology
March 05, 2021
The UK’s drug pricing regulator the National Institute for Health and Care Excellence (NICE) has decided not to recommend Kyowa Kirin’s Poteligeo (mogamulizumab) for routine use in the National Health Service (NHS) in England and Wales.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 44 45 Next page